Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics, Inc.

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

Yolo Group serves millions of users globally with gaming experiences and operates an ecosystem behind its brands.

Yolo Group

Voyager Therapeutics is a biotechnology company dedicated to leveraging human genetics to modify the course of and ultimately cure neurological diseases. Self-described as advancing transformative medicines for neurological diseases.

Metric
Company Name	Voyager Therapeutics, Inc.	BridgeBio Pharma	Hera BioLabs	Yolo Group
Symbol	VYGR
MSH ID	COM:VOYAGERTHERAPEUTICS	COM:BRIDGEBIOPHARMA	COM:HERABIOLABS	COM:YOLO
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Consumer Services
Industry	Biotechnology	Biotechnology	Biotechnology	Gambling & Casinos
Country	US	US	US	DE
Stage		Post-IPO Equity	Venture Round
Employee Count	162
Website	voyagertherapeutics.com	bridgebiopharma.com	herabiolabs.com	yolo.com
LinkedIn
Founders

Metric
Market Cap	439.50M
Enterprise Value
Monthly Web Traffic		23.81K	1.41K
Web Traffic Growth		0.19	-0.46
Valuation
Raised Capital		250M	1.07M

Metric
Revenue	250.01M
Revenue (LTM)
Revenue (NTM)
Gross Profit	245.57M
EBITDA	126.45M
Operating Income	122.01M
Net Income	132.33M
EPS	3.08
Diluted EPS	2.97
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	0.49
EBITDA Margin	0.51
Net Profit Margin	0.53
Return on Equity	0.64
Return on Assets	0.38
Return on Capital Employed	0.43

COM:VOYAGERTHERAPEUTICS

Voyager Therapeutics

Last Close

5.43

22/11 21:00

Market Cap

439.50M

Beta: -

Volume Today

359.89K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	6.18
P/B Ratio	1.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.34
EV Multiple	4.40

Metric
Days Sales Outstanding	9.99
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	123.30
Cash Conversion Cycle	-8.53
Asset Turnover	0.71

Metric
Operating Cash Flow	77.92M
Free Cash Flow	74.66M
Cash Flow to Debt	3.74
Operating Cash Flow/Sales	0.30
Free Cash Flow Yield	0.25

Metric
Cash & Equivalents	68.80M
Accounts Receivable	-83.23M
Inventory
Goodwill
Debt to Capitalization	0.12
Debt to Assets	0.07
Current Ratio	4.25
Quick Ratio	9.51

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.09
R&D to Revenue	0.68
SG&A to Revenue	0.29